The DOI matches its Crossref record; 28 of the 28 references it cites were found in a registry or an index.
Lipoprotein(a) Reduction in Persons with Cardiovascular Disease
Open accessAbstract
BACKGROUNDLipoprotein(a) levels are genetically determined and, when elevated, are a risk factor for cardiovascular disease and aortic stenosis.There are no approved pharmacologic therapies to lower lipoprotein(a) levels. METHODSWe conducted a randomized, double-blind, placebo-controlled, dose-ranging trial involving 286 patients with established cardiovascular disease and screening lipoprotein(a) levels of at least 60 mg per deciliter (150 nmol per liter).Patients received the hepatocyte-directed antisense oligonucleotide AKCEA-APO(a)-L Rx , referred to here as APO(a)-L Rx (20, 40, or 60 mg every 4 weeks; 20 mg every 2 weeks; or 20 mg every week), or saline placebo subcutaneously for 6 to 12 months.The lipoprotein(a) level was measured with an isoform-independent assay.The primary end point was the percent change in lipoprotein(a) level from baseline to month 6 of exposure (week 25 in the groups that received monthly doses and week 27 in the groups that received more frequent doses). RESULTSThe median baseline lipoprotein(a) levels in the six groups ranged from 204.5 to 246.6 nmol per liter.Administration of APO(a)-L Rx resulted in dose-dependent decreases in lipoprotein(a) levels, with mean percent decreases of 35% at a dose of 20 mg every 4 weeks, 56% at 40 mg every 4 weeks, 58% at 20 mg every 2 weeks, 72% at 60 mg every 4 weeks, and 80% at 20 mg every week, as compared with 6% with placebo (P values for the comparison with placebo ranged from 0.003 to <0.001).There were no significant differences between any APO(a)-L Rx dose and placebo with respect to platelet counts, liver and renal measures, or influenza-like symptoms.The most common adverse events were injection-site reactions.CONCLUSIONS APO(a)-L Rx reduced lipoprotein(a) levels in a dose-dependent manner in patients who had elevated lipoprotein(a) levels and established cardiovascular disease.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“At the same time, pelacarsen was well tolerated. Only injection site reactions were more frequently observed in the treatment group.”
From Established and Emerging Lipid-Lowering Drugs for Primary and Secondary Cardiovascular Prevention (2023) · cites this paper as [182]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“Consistently, in a randomized, double-blind, placebo-controlled phase 2 trial of 286 patients with elevated Lp(a) levels and established CVD, pelacarsen reduced Lp(a) in a dose-dependent manner by up to − 80% from baseline [182].”
From Established and Emerging Lipid-Lowering Drugs for Primary and Secondary Cardiovascular Prevention (2023) · cites this paper as [182]
The cited source says what the claim attributes to it.
In the citing paper
“Lp(a) has been identified as an independent risk marker for CVD as it exerts pro-atherogenic, pro-inflammatory, and pro-thrombotic effects which may play a critical role in the pathogenesis of atherosclerosis [182].”
From Established and Emerging Lipid-Lowering Drugs for Primary and Secondary Cardiovascular Prevention (2023) · cites this paper as [182]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
2016 ESC/EAS Guidelines for the Management of Dyslipidaemias
Catapano, A. L., Graham, I., De Backer, G., Wiklund, O., Chapman, M. J., Drexel, H., Hoes, A. W., Jennings, C. S., Landmesser, U., Pedersen, T. R., et al. (2016) · European Heart Journal · doi:10.1093/eurheartj/ehw272 · Cited by 3,162
Grundy, S. M., Stone, N. J., Bailey, A. L., Beam, C., Birtcher, K. K., Blumenthal, R. S., Braun, L. T., de Ferranti, S., Faiella-Tommasino, J., Forman, D. E., et al. (2019) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2018.11.002 · Cited by 1,751
A NEW SERUM TYPE SYSTEM IN MAN—THE Lp SYSTEM
Berg, K. (1963) · Acta Pathologica Microbiologica Scandinavica · doi:10.1111/j.1699-0463.1963.tb01808.x · Cited by 1,383
Lipoprotein(a), PCSK9 Inhibition, and Cardiovascular Risk: Insights From the FOURIER Trial
O’Donoghue, M. L., Fazio, S., Giugliano, R. P., Stroes, E. S. G., Kanevsky, E., Gouni-Berthold, I., Im, K., Lira Pineda, A., Wasserman, S. M., Češka, R., et al. (2019) · Circulation · doi:10.1161/circulationaha.118.037184 · Cited by 984
Self-citationCrooke, S. T., Witztum, J. L., Bennett, C. F., & Baker, B. F. (2018) · Cell Metabolism · doi:10.1016/j.cmet.2018.03.004 · Cited by 841
Self-citationViney, N. J., van Capelleveen, J. C., Geary, R. S., Xia, S., Tami, J. A., Yu, R. Z., Marcovina, S. M., Hughes, S. G., Graham, M. J., Crooke, R. M., et al. (2016) · The Lancet · doi:10.1016/s0140-6736(16)31009-1 · Cited by 754
Self-citationvan der Valk, F. M., Bekkering, S., Kroon, J., Yeang, C., den Bossche, J. V., van Buul, J. D., Ravandi, A., Nederveen, A. J., Verberne, H. J., Scipione, C. A., et al. (2016) · Circulation · doi:10.1161/circulationaha.116.020838 · Cited by 706
Self-citationLipoprotein Lp(a) and the risk for myocardial infarction
Kostner, G. M., Avogaro, P., Cazzolato, G., Marth, E., Bittolo-Bon, G., & Qunici, G. B. (1981) · Atherosclerosis · doi:10.1016/0021-9150(81)90103-9 · Cited by 687
Giugliano, R. P., Pedersen, T. R., Park, J.-G., De Ferrari, G. M., Gaciong, Z. A., Ceska, R., Toth, K., Gouni-Berthold, I., Lopez-Miranda, J., Schiele, F., et al. (2017) · The Lancet · doi:10.1016/s0140-6736(17)32290-0 · Cited by 682
Self-citationStructure, function, and genetics of lipoprotein (a)
Schmidt, K., Noureen, A., Kronenberg, F., & Utermann, G. (2016) · Journal of Lipid Research · doi:10.1194/jlr.r067314 · Cited by 671
Flagged first, then by citations
Cited by
Sorted by citations
The changing landscape of atherosclerosis
Libby, P. (2021) · Nature · doi:10.1038/s41586-021-03392-8 · Cited by 2,873
Kronenberg, F., Mora, S., Stroes, E. S. G., Ference, B. A., Arsenault, B. J., Berglund, L., Dweck, M. R., Koschinsky, M., Lambert, G., Mach, F., et al. (2022) · European Heart Journal · doi:10.1093/eurheartj/ehac361 · Cited by 1,449
Self-citationCriqui, M. H., Matsushita, K., Aboyans, V., Hess, C. N., Hicks, C. W., Kwan, T., McDermott, M. M., Misra, S., & Ujueta, F. (2021) · Circulation · doi:10.1161/cir.0000000000001005 · Cited by 828
Reyes-Soffer, G., Ginsberg, H. N., Berglund, L., Duell, P. B., Heffron, S. P., Kamstrup, P. R., Lloyd-Jones, D. M., Marcovina, S. M., Yeang, C., Koschinsky, M. L., et al. (2022) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/atv.0000000000000147 · Cited by 836
Antisense technology: an overview and prospectus
Crooke, S. T., Baker, B. F., Crooke, R. M., & Liang, X.-H. (2021) · Nature Reviews Drug Discovery · doi:10.1038/s41573-021-00162-z · Cited by 775
Connelly‐Smith, L. S., Alquist, C. R., Aqui, N. A., Hofmann, J. C., Klingel, R., Onwuemene, O. A., Patriquin, C. J., Pham, H. P., Sanchez, A. P., Schneiderman, J., et al. (2023) · Journal of Clinical Apheresis · doi:10.1002/jca.22043 · Cited by 751
2025 Focused Update of the 2019 ESC/EAS Guidelines for the management of dyslipidaemias
Mach, F., Koskinas, K. C., Roeters van Lennep, J. E., Tokgözoğlu, L., Badimon, L., Baigent, C., Benn, M., Binder, C. J., Catapano, A. L., De Backer, G. G., et al. (2025) · European Heart Journal · doi:10.1093/eurheartj/ehaf190 · Cited by 688
Self-citationSmall Interfering RNA to Reduce Lipoprotein(a) in Cardiovascular Disease
O’Donoghue, M. L., Rosenson, R. S., Gencer, B., López, J. A. G., Lepor, N. E., Baum, S. J., Stout, E., Gaudet, D., Knüsel, B., Kuder, J., et al. (2022) · New England Journal of Medicine · doi:10.1056/nejmoa2211023 · Cited by 618
Self-citationPatel, A. P., Wang, M., Pirruccello, J. P., Ellinor, P. T., Ng, K., Kathiresan, S., & Khera, A. V. (2021) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/atvbaha.120.315291 · Cited by 567
Duan, Y., Gong, K., Xu, S., Zhang, F., Meng, X., & Han, J. (2022) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-022-01125-5 · Cited by 538
A Modern Approach to Dyslipidemia
Berberich, A. J., & Hegele, R. A. (2021) · Endocrine Reviews · doi:10.1210/endrev/bnab037 · Cited by 529
Delivery of oligonucleotides to the liver with GalNAc: From research to registered therapeutic drug.
Debacker, A. J., Voutila, J., Catley, M., Blakey, D., & Habib, N. (2020) · Molecular Therapy · doi:10.1016/j.ymthe.2020.06.015 · Cited by 424
Lipoprotein(a) and its Significance in Cardiovascular Disease
Lau, F. D., & Giugliano, R. P. (2022) · JAMA Cardiology · doi:10.1001/jamacardio.2022.0987 · Cited by 377
Antisense technology: A review
Crooke, S. T., Liang, X., Baker, B. F., & Crooke, R. M. (2021) · Journal of Biological Chemistry · doi:10.1016/j.jbc.2021.100416 · Cited by 350
Calcific aortic valve disease: mechanisms, prevention and treatment
Moncla, L.-H. M., Briend, M., Bossé, Y., & Mathieu, P. (2023) · Nature Reviews Cardiology · doi:10.1038/s41569-023-00845-7 · Cited by 306
Calcific aortic valve disease: from molecular and cellular mechanisms to medical therapy
Kraler, S., Blaser, M. C., Aikawa, E., Camici, G. G., & Lüscher, T. F. (2022) · European Heart Journal · doi:10.1093/eurheartj/ehab757 · Cited by 281
Residual Cardiovascular Risk at Low LDL: Remnants, Lipoprotein(a), and Inflammation
Hoogeveen, R. C., & Ballantyne, C. M. (2020) · Clinical Chemistry · doi:10.1093/clinchem/hvaa252 · Cited by 322
Nissen, S. E., Wolski, K., Balog, C., Swerdlow, D. I., Scrimgeour, A., Rambaran, C., Wilson, R. J., Boyce, M., Ray, K. K., Cho, L., et al. (2022) · JAMA · doi:10.1001/jama.2022.5050 · Cited by 308
Self-citationInflammation, Cholesterol, Lipoprotein(a), and 30-Year Cardiovascular Outcomes in Women
Ridker, P. M., Moorthy, M. V., Cook, N. R., Rifai, N., Lee, I.-M. M., & Buring, J. E. (2024) · New England Journal of Medicine · doi:10.1056/nejmoa2405182 · Cited by 317
Lipoprotein(a) and cardiovascular disease
Nordestgaard, B. G., & Langsted, A. (2024) · The Lancet · doi:10.1016/s0140-6736(24)01308-4 · Cited by 315
Self-citationThe powerful world of antisense oligonucleotides: From bench to bedside
Quéméner, A. M., Bachelot, L., Forestier, A., Donnou‐Fournet, E., Gilot, D., & Galibert, M. (2020) · Wiley Interdisciplinary Reviews - RNA · doi:10.1002/wrna.1594 · Cited by 284
Apolipoproteins in vascular biology and atherosclerotic disease
Mehta, A., & Shapiro, M. D. (2022) · Nature Reviews Cardiology · doi:10.1038/s41569-021-00613-5 · Cited by 273
Self-citationLipoprotein(a) and Cardiovascular Disease
Kamstrup, P. R. (2020) · Clinical Chemistry · doi:10.1093/clinchem/hvaa247 · Cited by 266
Preclinical development and phase 1 trial of a novel siRNA targeting lipoprotein(a)
Koren, M. J., Moriarty, P. M., Baum, S. J., Neutel, J., Hernandez-Illas, M., Weintraub, H. S., Florio, M., Kassahun, H., Melquist, S., Varrieur, T., et al. (2022) · Nature Medicine · doi:10.1038/s41591-021-01634-w · Cited by 239
Self-citationLepodisiran, an Extended-Duration Short Interfering RNA Targeting Lipoprotein(a)
Nissen, S. E., Linnebjerg, H., Xi Zhong, S. H. E. N., Wolski, K., Ma, X., Lim, S., Michael, L. F., Ruotolo, G., Gribble, G., Návar, A. M., et al. (2023) · JAMA · doi:10.1001/jama.2023.21835 · Cited by 235
2023 Chinese guideline for lipid management
Li, J., Zhao, S., Zhao, D. H., Lü, G., Peng, D., Liu, J., Chen, Z., Guo, Y., Wu, N., Yan, S.-K., et al. (2023) · Frontiers in Pharmacology · doi:10.3389/fphar.2023.1190934 · Cited by 241
From target discovery to clinical drug development with human genetics
Trajanoska, K., Bhérer, C., Taliun, D., Zhou, S., Richards, J. B., & Mooser, V. (2023) · Nature · doi:10.1038/s41586-023-06388-8 · Cited by 229
Tardif, J.-C., Karwatowska-Prokopczuk, E., Amour, E. S., Ballantyne, C. M., Shapiro, M. D., Moriarty, P. M., Baum, S. J., Hurh, E., Bartlett, V. J., Kingsbury, J., et al. (2022) · European Heart Journal · doi:10.1093/eurheartj/ehab820 · Cited by 210
Self-citationEffect of Pelacarsen on Lipoprotein(a) Cholesterol and Corrected Low-Density Lipoprotein Cholesterol
Yeang, C., Karwatowska‐Prokopczuk, E., Su, F., Dinh, B., Xia, S., Witztum, J. L., & Tsimikas, S. (2022) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2021.12.032 · Cited by 222
Self-citationMuvalaplin, an Oral Small Molecule Inhibitor of Lipoprotein(a) Formation
Nicholls, S. J., Nissen, S. E., Fleming, C., Urva, S., Suico, J. G., Berg, P. H., Linnebjerg, H., Ruotolo, G., Turner, P. K., & Michael, L. F. (2023) · JAMA · doi:10.1001/jama.2023.16503 · Cited by 217
The Evolving Understanding and Approach to Residual Cardiovascular Risk Management
Dhindsa, D. S., Sandesara, P. B., Shapiro, M. D., & Wong, N. D. (2020) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2020.00088 · Cited by 208
Self-citationMehta, A., Vasquez, N., Ayers, C. R., Patel, J., Hooda, A., Khera, A., Blumenthal, R. S., Shapiro, M. D., Rodríguez, C. J., Tsai, M. Y., et al. (2022) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2021.11.058 · Cited by 184
Self-citationNucleic acid drugs: recent progress and future perspectives
Sun, X., Setrerrahmane, S., Li, C., Hu, J., & Xu, H. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-02035-4 · Cited by 225
Lipoproteins and fatty acids in chronic kidney disease: molecular and metabolic alterations
Noels, H., Lehrke, M., Vanholder, R. C., & Jankowski, J. (2021) · Nature Reviews Nephrology · doi:10.1038/s41581-021-00423-5 · Cited by 183
Newman, C. B., Blaha, M. J., Boord, J. B., Cariou, B., Chait, A., Fein, H. G., Ginsberg, H. N., Goldberg, I. J., Murad, M. H., Subramanian, S., et al. (2020) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgaa674 · Cited by 182
Lepodisiran — A Long-Duration Small Interfering RNA Targeting Lipoprotein(a)
Nissen, S. E., Ni, W., Xi Zhong, S. H. E. N., Wang, Q., Návar, A. M., Nicholls, S. J., Wolski, K., Michael, L., Haupt, A., & Krege, J. H. (2025) · New England Journal of Medicine · doi:10.1056/nejmoa2415818 · Cited by 183
Cho, L., Nicholls, S. J., Nordestgaard, B. G., Landmesser, U., Tsimikas, S., Blaha, M. J., Leitersdorf, E., Lincoff, A. M., Lesogor, A., Manning, B., et al. (2025) · American Heart Journal · doi:10.1016/j.ahj.2025.03.019 · Cited by 169
Self-citationHigh-Sensitivity C-Reactive Protein Modifies the Cardiovascular Risk of Lipoprotein(a)
Zhang, W., Speiser, J. L., Ye, F., Tsai, M. Y., Cainzos‐Achirica, M., Nasir, K., Herrington, D. M., & Shapiro, M. D. (2021) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2021.07.016 · Cited by 169
Self-citation2025 Focused Update of the 2019 ESC/EAS Guidelines for the management of dyslipidaemias
Mach, F., Koskinas, K. C., van Lennep, J. E. R., Tokgözoğlu, L. S., Badimón, L., Baigent, C., Benn, M., Binder, C. J., Catapano, A. L., Backer, G. D., et al. (2025) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2025.120479 · Cited by 190
Self-citationTrinder, M., Uddin, M. M., Finneran, P., Aragam, K. G., & Natarajan, P. (2020) · JAMA Cardiology · doi:10.1001/jamacardio.2020.5398 · Cited by 168
Contemporary Medical Management of Peripheral Artery Disease
Bonaca, M. P., Hamburg, N. M., & Creager, M. A. (2021) · Circulation Research · doi:10.1161/circresaha.121.318258 · Cited by 170
Oral Muvalaplin for Lowering of Lipoprotein(a)
Nicholls, S. J., Ni, W., Rhodes, G. M., Nissen, S. E., Návar, A. M., Michael, L. F., Haupt, A., & Krege, J. H. (2024) · JAMA · doi:10.1001/jama.2024.24017 · Cited by 162
Arvanitis, M., & Lowenstein, C. J. (2023) · Annals of Internal Medicine · doi:10.7326/aitc202306200 · Cited by 174
Aspirin for Primary Prevention of Cardiovascular Events in Relation to Lipoprotein(a) Genotypes
Lacaze, P. A., Bakshi, A., Riaz, M., Polekhina, G., Owen, A. J., Bhatia, H. S., Natarajan, P., Wolfe, R. S., Beilin, L. J., Nicholls, S. J., et al. (2022) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2022.07.027 · Cited by 166
Self-citationZerlasiran—A Small-Interfering RNA Targeting Lipoprotein(a)
Nissen, S. E., Wang, Q., Nicholls, S. J., Návar, A. M., Ray, K. K., Schwartz, G. G., Szarek, M. J., Stroes, E. S. G., Troquay, R. P. T., Dorresteijn, J. A. N., et al. (2024) · JAMA · doi:10.1001/jama.2024.21957 · Cited by 157
Self-citationEmerging RNA Therapeutics to Lower Blood Levels of Lp(a)
Tsimikas, S., Moriarty, P. M., & Stroes, E. S. G. (2021) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2021.01.051 · Cited by 155
Self-citationLipoprotein(a) measurement issues: Are we making a mountain out of a molehill?
Kronenberg, F. (2022) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2022.04.008 · Cited by 156
Oxidized phospholipids in cardiovascular disease
Tsimikas, S., & Witztum, J. L. (2023) · Nature Reviews Cardiology · doi:10.1038/s41569-023-00937-4 · Cited by 166
Self-citationLipoprotein(a) levels in a global population with established atherosclerotic cardiovascular disease
Nissen, S. E., Wolski, K., Cho, L., Nicholls, S. J., Kastelein, J. J. P., Leitersdorf, E., Landmesser, U., Blaha, M. J., Lincoff, A. M., Morishita, R., et al. (2022) · Open Heart · doi:10.1136/openhrt-2022-002060 · Cited by 148
Self-citationFerroptosis and cardiovascular disease: role of free radical-induced lipid peroxidation
Chen, X., Li, X., Xu, X., Li, L., Liang, N., Zhang, L., Lv, J., Wu, Y., & Yin, H. (2021) · Free Radical Research · doi:10.1080/10715762.2021.1876856 · Cited by 145
Kronenberg, F., Mora, S., Stroes, E. S. G., Ference, B. A., Arsenault, B. J., Berglund, L., Dweck, M. R., Koschinsky, M. L., Lambert, G. C., Mach, F., et al. (2023) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2023.04.012 · Cited by 146
Self-citationSmall, A., Pournamdari, A. B., Melloni, G. E. M., Scirica, B. M., Bhatt, D. L., Raz, I., Braunwald, E., Giugliano, R. P., Sabatine, M. S., Peloso, G. M., et al. (2024) · JAMA Cardiology · doi:10.1001/jamacardio.2023.5605 · Cited by 136
Lipoprotein(a), Oxidized Phospholipids, and Coronary Artery Disease Severity and Outcomes
Gilliland, T., Liu, Y., Mohebi, R., Miksenas, H., Haidermota, S., Wong, M., Hu, X., Cristino, J., Browne, A., Plutzky, J., et al. (2023) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2023.02.050 · Cited by 110
Self-citationCrooke, S. T., Seth, P. P., Vickers, T. A., & Liang, X. (2020) · Journal of the American Chemical Society · doi:10.1021/jacs.0c04928 · Cited by 131
Diagnosis and Management of Stable Angina
Joshi, P. H., & de Lemos, J. A. (2021) · JAMA · doi:10.1001/jama.2021.1527 · Cited by 124
Animal Models of Atherosclerosis–Supportive Notes and Tricks of the Trade
Gisterå, A., Ketelhuth, D. F. J., Malin, S., & Hansson, G. K. (2022) · Circulation Research · doi:10.1161/circresaha.122.320263 · Cited by 127
RNA therapeutics: updates and future potential
Zhang, C., & Zhang, B. (2022) · Science China Life Sciences · doi:10.1007/s11427-022-2171-2 · Cited by 125
Nucleic Acid Therapeutics: Successes, Milestones, and Upcoming Innovation
Belgrad, J., Fakih, H. H., & Khvorova, A. (2024) · Nucleic Acid Therapeutics · doi:10.1089/nat.2023.0068 · Cited by 130
Stiekema, L. C. A., Prange, K. H. M., Hoogeveen, R. M., Verweij, S. L., Kroon, J., Schnitzler, J. G., Dzobo, K. E., Cupido, A. J., Tsimikas, S., Stroes, E. S. G., et al. (2020) · European Heart Journal · doi:10.1093/eurheartj/ehaa171 · Cited by 119
Self-citationYeang, C., Witztum, J. L., & Tsimikas, S. (2021) · Journal of Lipid Research · doi:10.1016/j.jlr.2021.100053 · Cited by 118
Self-citationBerman, A. N., Biery, D. W., Besser, S. A., Singh, A., Shiyovich, A., Weber, B., Huck, D. M., Divakaran, S., Hainer, J. M., Kaur, G., et al. (2024) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2023.12.031 · Cited by 124
Bhatia, H. S., Wandel, S., Willeit, P., Lesogor, A., Bailey, K., Ridker, P. M., Nestel, P. J., Simes, R. J., Tonkin, A. M., Schwartz, G. G., et al. (2024) · Circulation · doi:10.1161/circulationaha.124.069556 · Cited by 127
Self-citationDyslipidemia, inflammation, calcification, and adiposity in aortic stenosis: a genome-wide study
Yu Chen, H., Dina, C., Small, A. M., Shaffer, C. M., Levinson, R. T., Helgadóttir, A., Capoulade, R., Munter, H. M., Martinsson, A., Cairns, B. J., et al. (2023) · European Heart Journal · doi:10.1093/eurheartj/ehad142 · Cited by 116
Lipoprotein(a) as a Pharmacological Target: Premises, Promises, and Prospects
Greco, A., Finocchiaro, S., Spagnolo, M., Faro, D. C., Mauro, M. S., Raffo, C., Sangiorgio, G., Imbesi, A., Laudani, C., Mazzone, P. M., et al. (2025) · Circulation · doi:10.1161/circulationaha.124.069210 · Cited by 126
Lu, Y., Cui, X., Zhang, L., Wang, X., Xu, Y., Qin, Z., Liu, G., Wang, Q., Tian, K., Lim, K. S., et al. (2022) · Aging and Disease · doi:10.14336/ad.2021.0929 · Cited by 117
Evaluating Medical Therapy for Calcific Aortic Stenosis
Lindman, B. R., Sukul, D., Dweck, M. R., Madhavan, M. V., Arsenault, B. J., Coylewright, M. J., Merryman, W. D., Newby, D. E., Lewis, J., Harrell, F. E., et al. (2021) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2021.09.1367 · Cited by 115
O’Donoghue, M. L., López, J. A. G., Knüsel, B., Gencer, B., Wang, H., Wu, Y., Kassahun, H., & Sabatine, M. S. (2022) · American Heart Journal · doi:10.1016/j.ahj.2022.05.004 · Cited by 112
Vinci, P., Girolamo, F. G. D., Panizon, E., Tosoni, L. M., Cerrato, C., Pellicori, F., Altamura, N., Pirulli, A., Zaccari, M., Biasinutto, C., et al. (2023) · International Journal of Environmental Research and Public Health · doi:10.3390/ijerph20186721 · Cited by 119
2023 China Guidelines for Lipid Management
Li, J., Zhao, S., Zhao, D., Lü, G., Peng, D., Liu, J., Chen, Z., Guo, Y., Wu, N., Yan, S.-K., et al. (2023) · 老年心脏病学杂志：英文版 · doi:10.26599/1671-5411.2023.09.008 · Cited by 120
Established and Emerging Lipid-Lowering Drugs for Primary and Secondary Cardiovascular Prevention
Michaeli, D. T., Michaeli, J. C., Albers, S., Boch, T., & Michaeli, T. (2023) · American Journal of Cardiovascular Drugs · doi:10.1007/s40256-023-00594-5 · Cited by 109
“Consistently, in a randomized, double-blind, placebo-controlled phase 2 trial of 286 patients with elevated Lp(a) levels and established CVD, pelacarsen reduced Lp(a) in a dosedependent manner by up to − 80% from baseline [182].”
BackgroundClinical Trial Design for Lipoprotein(a)-Lowering Therapies
Malick, W. A., Goonewardena, S. N., Köenig, W., & Rosenson, R. S. (2023) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2023.02.033 · Cited by 112
Antisense drug discovery and development technology considered in a pharmacological context
Crooke, S. T., Liang, X., Crooke, R. M., Baker, B. F., & Geary, R. S. (2020) · Biochemical Pharmacology · doi:10.1016/j.bcp.2020.114196 · Cited by 109
Repeat Measures of Lipoprotein(a) Molar Concentration and Cardiovascular Risk
Trinder, M., Paruchuri, K., Haidermota, S., Bernardo, R. C., Zekavat, S. M., Gilliland, T., Januzzi, J. L., & Natarajan, P. (2022) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2021.11.055 · Cited by 106
Novel and future lipid-modulating therapies for the prevention of cardiovascular disease
Brandts, J., & Ray, K. K. (2023) · Nature Reviews Cardiology · doi:10.1038/s41569-023-00860-8 · Cited by 109
Cui, D., Yu, X., Guan, Q., Shen, Y., Liao, J., Liu, Y., & Su, Z. (2025) · Molecular Biomedicine · doi:10.1186/s43556-025-00321-3 · Cited by 126
Thomas, P. E., Vedel‐Krogh, S., Nielsen, S. F., Nordestgaard, B. G., & Kamstrup, P. R. (2023) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2023.10.009 · Cited by 106
Self-citationFrom traditional pharmacological towards nucleic acid-based therapies for cardiovascular diseases
Landmesser, U., Poller, W. C., Tsimikas, S., Most, P., Paneni, F., & Lüscher, T. F. (2020) · European Heart Journal · doi:10.1093/eurheartj/ehaa229 · Cited by 102
Self-citationArnold, M., Schweizer, J., Nakas, C. T., Schütz, V., Westphal, L. P., Inauen, C., Pokorny, T., Luft, A. R., Leichtle, A. B., Arnold, M., et al. (2021) · European Heart Journal · doi:10.1093/eurheartj/ehab081 · Cited by 99
Scharner, J., & Aznarez, I. (2020) · Molecular Therapy · doi:10.1016/j.ymthe.2020.12.022 · Cited by 96
Lipoprotein(a)—The Crossroads of Atherosclerosis, Atherothrombosis and Inflammation
Ugovšek, S., & Šebeštjen, M. (2021) · Biomolecules · doi:10.3390/biom12010026 · Cited by 102
Lipoprotein(a) is associated with the onset but not the progression of aortic valve calcification
Kaiser, Y., van der Toorn, J. E., Singh, S. S., Zheng, K. H., Kavousi, M., Sijbrands, E. J. G., Stroes, E. S. G., Vernooij, M. W., de Rijke, Y. B., Boekholdt, S. M., et al. (2022) · European Heart Journal · doi:10.1093/eurheartj/ehac377 · Cited by 98
Self-citationTargeting RNA With Antisense Oligonucleotides and Small Interfering RNA in Dyslipidemias
Katzmann, J. L., Packard, C. J., Chapman, M. J., Katzmann, I., & Laufs, U. (2020) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2020.05.070 · Cited by 99
Small non-coding RNA therapeutics for cardiovascular disease
Shah, A. M., & Giacca, M. (2022) · European Heart Journal · doi:10.1093/eurheartj/ehac463 · Cited by 97
Viney, N. J., Guo, S., Tai, L.-J., Baker, B. F., Aghajan, M., Jung, S. W., Yu, R. Z., Booten, S. L., Murray, H., Machemer, T., et al. (2020) · ESC Heart Failure · doi:10.1002/ehf2.13154 · Cited by 98
Self-citationLipoprotein(a) in Youth and Prediction of Major Cardiovascular Outcomes in Adulthood
Raitakari, O. T., Kartiosuo, N., Pahkala, K., Hutri‐Kähönen, N., Bazzano, L., Chen, W., Urbina, E. M., Jacobs, D. R., Sinaiko, A. R., Steinberger, J., et al. (2022) · Circulation · doi:10.1161/circulationaha.122.060667 · Cited by 96
Antisense Inhibition of Angiotensinogen With IONIS-AGT-LRx
Morgan, E. S., Tami, Y., Hu, K., Brambatti, M., Mullick, A. E., Geary, R. S., Bakris, G. L., & Tsimikas, S. (2021) · JACC Basic to Translational Science · doi:10.1016/j.jacbts.2021.04.004 · Cited by 97
Self-citationDiet and Lp(a): Does Dietary Change Modify Residual Cardiovascular Risk Conferred by Lp(a)?
Enkhmaa, B., Petersen, K. H., Kris‐Etherton, P. M., & Berglund, L. (2020) · Nutrients · doi:10.3390/nu12072024 · Cited by 98
Lipoprotein(a) and Cardiovascular Disease in Chinese Population
Li, J., Ma, C.-S., Zhao, D. H., Yan, X.-W., Li, J., Ma, C., Zhao, D. H., Yan, X.-W., Ye, P., Chen, H., et al. (2022) · JACC Asia · doi:10.1016/j.jacasi.2022.08.015 · Cited by 96
Lipoprotein(a) and Cardiovascular Diseases ― Revisited ―
Jang, A. Y., Han, S. H., Sohn, I. S., Oh, P. C., & Koh, K. K. (2020) · Circulation Journal · doi:10.1253/circj.cj-20-0051 · Cited by 97
Nissen, S. E., Wolski, K., Watts, G. F., Koren, M. J., Fok, H., Nicholls, S. J., Rider, D. A., Cho, L., Romano, S., Melgaard, C., et al. (2024) · JAMA · doi:10.1001/jama.2024.4504 · Cited by 91
Soroudi, S., Jaafari, M. R., & Arabi, L. (2024) · Journal of Controlled Release · doi:10.1016/j.jconrel.2024.06.023 · Cited by 96
The dedicated “Lp(a) clinic”: A concept whose time has arrived?
Tsimikas, S., & Stroes, E. S. G. (2020) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2020.03.003 · Cited by 94
Self-citationInflammation and Cardiovascular Disease: The Future
Arnold, N., Lechner, K., Waldeyer, C., Shapiro, M. D., & Köenig, W. (2021) · European Cardiology Review · doi:10.15420/ecr.2020.50 · Cited by 93
Self-citationPrimary Prevention of Subclinical Atherosclerosis in Young Adults
Devesa, A., Ibáñez, B., Malick, W. A., Tinuoye, E. O., Bustamante, J., Peyra, C., Rosenson, R. S., Bhatt, D. L., Stone, G. W., & Fuster, V. (2023) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2023.09.817 · Cited by 101
Lipoprotein(a) in atherosclerosis: from pathophysiology to clinical relevance and treatment options
Likozar, A. R., Zavrtanik, M., & Šebeštjen, M. (2020) · Annals of Medicine · doi:10.1080/07853890.2020.1775287 · Cited by 91
Existing and emerging strategies to lower Lipoprotein(a)
Schwartz, G. G., & Ballantyne, C. M. (2022) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2022.04.020 · Cited by 86
Lipoprotein(a): a genetic marker for cardiovascular disease and target for emerging therapies
Cesaro, A., Schiavo, A., Moscarella, E., Coletta, S., Conte, M., Gragnano, F., Fimiani, F., Monda, E., Caiazza, M., Limongelli, G., et al. (2020) · Journal of Cardiovascular Medicine · doi:10.2459/jcm.0000000000001077 · Cited by 84
Lipoprotein(a): Knowns, unknowns and uncertainties
Ruscica, M., Sirtori, C. R., Corsini, A., Watts, G. F., & Sahebkar, A. (2021) · Pharmacological Research · doi:10.1016/j.phrs.2021.105812 · Cited by 84
New, Novel Lipid-Lowering Agents for Reducing Cardiovascular Risk: Beyond Statins
Kim, K., Ginsberg, H. N., & Choi, S. H. (2022) · Diabetes & Metabolism Journal · doi:10.4093/dmj.2022.0198 · Cited by 88
Panvascular medicine: an emerging discipline focusing on atherosclerotic diseases
Zhou, X., Yu, L., Zhao, Y., & Ge, J. (2022) · European Heart Journal · doi:10.1093/eurheartj/ehac448 · Cited by 84
Metadata
- Authors
- Tsimikas, S., Karwatowska-Prokopczuk, E., Gouni-Berthold, I., Tardif, J.-C., Baum, S. J., Steinhagen-Thiessen, E., Shapiro, M. D., Stroes, E. S., Moriarty, P. M., Nordestgaard, B. G., Xia, S., Guerriero, J., Viney, N. J., O’Dea, L., & Witztum, J. L.
- Affiliations
- University of Cologne (DE)
- From the Divisions of Cardiovascular Medicine (S.T.) and Endocrinology and Metabolism (J.L.W.), University of California, San Diego, La Jolla, and Ionis Pharmaceuticals, Carlsbad (S.T., S.X., N.J.V.) — both in California; Akcea Therapeutics, Boston (E.K.-P., J.G., L.O.); Polyclinic for Endocrinology, Diabetes and Preventive Medicine, University of Cologne, Cologne, Germany (I.G.-B.); Montreal Heart Institute, Université de Montréal, Montreal (J.-C.T.); Excel Medical Clinical Trials, Boca Raton, FL ...
- Oregon Health & Science University (US)
- University of Copenhagen (DK)
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2020-01-16
- Volume
- 382
- Issue
- 3
- Pages
- 244-255
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2997944188
- Semantic Scholar
- 725c405ccc1ec3726f9ba922da158107891d134f
- Cited by
- 1,094
- References
- 28
- Citations by year
- 2026: 204 · 2025: 176 · 2024: 156 · 2023: 149 · 2022: 159 · 2021: 153 · 2020: 96
- FWCI
- 127.17
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Kölner Universitäts PublikationsServer (Universität zu Köln) (publishedVersion)
- Pure Amsterdam UMC (publishedVersion)
- Data Archiving and Networked Services (DANS) (submittedVersion)
- Research at the University of Copenhagen (University of Copenhagen) (submittedVersion)
- Funders
- Akcea Therapeutics
- Topics
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipoproteins and Cardiovascular Health
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipid metabolism and disorders
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Biochemistry › Cholesterol and Lipid Metabolism
- Keywords
- lipoprotein(a), antisense oligonucleotides, cardiovascular disease, injection site reactions, genetic risk factors
- MeSH terms
- Adult, Aged, Hypolipidemic Agents, Cardiovascular Diseases, Cholesterol, Dose-Response Relationship, Drug, Double-Blind Method, Female, Humans, Male, Middle Aged, Oligonucleotides, Risk Factors, Least-Squares Analysis, Lipoprotein(a), Hydroxymethylglutaryl-CoA Reductase Inhibitors
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
